Regeneron Pharmaceuticals Earnings Preview: Analysts Adjust Metrics

Author: Addison Perry Updated: 08-01-2025 05:28 AM

Regeneron Pharmaceuticals Earnings Prediction

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is set to unveil its earnings report for the upcoming quarter soon. Analysts have projected that the company will announce earnings at approximately $8.43 per share. This figure represents a notable decline compared to last year's earnings of $11.56 per share.

Quarterly Revenue Anticipations

For the second quarter, expectations are that Regeneron will generate revenue totaling around $3.28 billion. In comparison, the corresponding quarter last year saw revenue of approximately $3.55 billion. This decline highlights challenges the company may be encountering amid a changing landscape in the pharmaceutical sector.

Recent FDA Approval

Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic (linvoseltamab-gcpt). This medication is intended for adult patients facing relapsed or refractory multiple myeloma (MM) who have undergone at least four previous therapy lines. This approval marks a significant milestone in Regeneron's continual efforts to address pressing medical needs.

Stock Performance and Current Price

In the lead-up to its earnings announcement, Regeneron Pharmaceuticals' stock experienced a minor dip, closing at $545.46, which translates to a decrease of about 1.6%. This slight decline may raise concerns among investors as they consider their strategies moving forward.

Analyst Ratings Update

Taking a glance at the latest ratings from various analysts, several have adjusted their expectations for Regeneron's stock performance. Here's what leading analysts have to say:

UBS analyst Trung Huynh reiterated a Neutral rating but increased the price target from $560 to $584.
Morgan Stanley analyst Matthew Harrison reaffirmed an Overweight rating but slightly lowered the price target from $755 to $754.
Citigroup analyst Geoff Meacham maintained a Buy rating with a revised price target, dropping it from $700 to $650.
Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight, reducing the price target from $700 to $580.
Guggenheim analyst Yatin Suneja continued to hold a Buy rating, cutting the price target significantly from $940 to $810.

Investor Considerations for REGN

For those contemplating investment in REGN stock, it is essential to pay attention to these revised analyst rankings as they provide critical insights into the potential trajectory of the stock post-earnings release. The collective sentiment from analysts can offer guidance in navigating this complex market landscape.

Frequently Asked Questions

What earnings are expected for Regeneron Pharmaceuticals in Q2?

Analysts expect Regeneron to report earnings of approximately $8.43 per share for the second quarter.

How much revenue is Regeneron projected to generate?

The company is anticipated to generate about $3.28 billion in revenue for the quarter.

What recent FDA approval did Regeneron Pharmaceuticals receive?

Regeneron received accelerated FDA approval for Lynozyfic, aimed at treating relapsed or refractory multiple myeloma.

What is the current stock price of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' shares closed at $545.46, reflecting a 1.6% decrease.

What are analysts saying about Regeneron's stock?

Analysts have varied opinions, with some affirming ratings while adjusting price targets amidst the evolving market dynamics.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.